By analyzing cases of more aggressive tumors such as the 12 Triple-negative breast cancer patients (TNBC) (Table 3), all with G2 or G3 infiltrating ductal carcinoma, we identified 6 Pathogenic and Likely-pathogenic variants: 1 in ATM, 1 in BRIP1, 2 in CHEK2, 1 in RAD51D and 1 in TP53. In 6 patients, 4 VUSs (3 in ATM and 1 in PTEN never recorded before) and 2 Likely-benign variants were identified. This evidence concerns the gene TP53 and triple-negative breast carcinoma.